AstraZeneca, in alliance with Saint Luke’s Mid America Heart Institute, has started a Phase III clinical trial of its diabetes drug Farxiga (dapagliflozin) to treat hospitalised Covid-19 patients at risk of serious complications.
Farxiga is an oral, once-daily sodium-glucose transport protein 2 (SGLT2) inhibitor indicated for adults with insufficiently controlled type 2 diabetes (T2D), as an adjunct to diet and exercise.
Go deeper with GlobalData
The new randomised, global trial, named DARE-19, will evaluate the drug’s ability to reduce the risk of disease progression, clinical complications, and death from Covid-19 in patients with CV, metabolic or kidney risk factors.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
